LAVAL, Quebec, Nov. 21, 2017 /PRNewswire/ -- Valeant
Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX)
("Valeant" or the "Company") announced today that it has closed its
previously announced offering (the "Offering") of $750,000,000 aggregate principal amount of its
5.500% senior secured notes due 2025 (the "Notes"). The Notes are
additional notes and form part of the same series as Valeant's
existing 5.500% senior secured notes due 2025. Valeant used the net
proceeds from the offering of the Notes, along with cash on hand,
to prepay (on a pro rata basis) a portion of its outstanding Series
F Tranche B Term Loans due 2022 and to pay related fees and
expenses.
Subsequent to the closing of the Offering and the related
prepayment, the Company successfully completed the repricing of its
Series F Tranche B Term Loans. The amendment reduces the annual
interest rate on the Series F Tranche B Term Loans by 1.25% and
makes certain other changes.
About Valeant
Valeant Pharmaceuticals International,
Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical
company that develops, manufactures and markets a broad range of
pharmaceutical products primarily in the areas of dermatology,
gastrointestinal disorders, eye health, neurology and branded
generics.
Investor
Contact:
|
Media
Contact:
|
|
Arthur
Shannon
|
Lainie
Keller
|
|
arthur.shannon@valeant.com
|
lainie.keller@valeant.com
|
|
(514)
856-3855
|
(908)
927-0617
|
|
(877) 281-6642 (toll
free)
|
|
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/valeant-announces-closing-of-add-on-secured-notes-and-credit-agreement-amendment-300560140.html
SOURCE Valeant Pharmaceuticals International, Inc.